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Deficiency in hormone-sensitive lipase
accelerates the development of pancreatic
cancer in conditional KrasG12D mice
Mu Xu1†, Hui-Hua Chang1,3†, Xiaoman Jung1, Aune Moro1, Caroline Ei Ne Chou1, Jonathan King1, O. Joe Hines1,
James Sinnett-Smith2,3, Enrique Rozengurt2,3 and Guido Eibl1,3*
Abstract
Background: Hormone sensitive lipase (HSL) is a neutral lipase that preferentially catalyzes the hydrolysis of
diacylglycerol contributing to triacylglycerol breakdown in the adipose tissue. HSL has been implicated to play a
role in tumor cachexia, a debilitating syndrome characterized by progressive loss of adipose tissue. Consequently,
pharmacological inhibitors of HSL have been proposed for the treatment of cancer-associated cachexia. In the
present study we used the conditional KrasG12D (KC) mouse model of pancreatic ductal adenocarcinoma (PDAC)
with a deficiency in HSL to determine the impact of HSL suppression on the development of PDAC.
Methods: KC;Hsl+/+ and KC;Hsl−/− mice were fed standard rodent chow for 20 weeks. At sacrifice, the incidence of
PDAC was determined and inflammation in the mesenteric adipose tissue and pancreas was assessed histologically
and by immunofluorescence. To determine statistical significance, ANOVA and two-tailed Student’s t-tests were
performed. To compare PDAC incidence, a two-sided Fisher’s exact test was used.
Results: Compared to KC;Hsl+/+ mice, KC;Hsl−/− mice gained similar weight and displayed adipose tissue and
pancreatic inflammation. In addition, KC;Hsl−/− mice had reduced levels of plasma insulin and leptin. Importantly,
the increased adipose tissue and pancreatic inflammation was associated with a significant increase in PDAC
incidence in KC;Hsl−/− mice.
Conclusions: HSL deficiency is associated with adipose tissue and pancreatic inflammation and accelerates PDAC
development in the KC mouse model.
Keywords: Pancreatic cancer, Hormone sensitive lipase, Adipose tissue inflammation, Pancreatic inflammation,
Animal model
Background
Hormone sensitive lipase (HSL) is an intracellular, neutral
lipase that catalyzes the hydrolysis of triacylglycerol, diac-
ylglycerol, monoacylglycerol, cholesteryl esters, and retinyl
esters [1]. Its activity against diacylglycerol is several-fold
higher than against triacylglycerol and monoacylglycerol.
Adipose triglyceride lipase (ATGL) and HSL are therefore
the major enzymes contributing to triacylglycerol break-
down in the adipose tissue [2]. Interestingly, an increase in
the level and activity of HSL has been implicated in the
pathogenesis of cachexia [3, 4], a debilitating syndrome
characterized by progressive loss of adipose tissue via
increased lipolysis [2–5]. Consequently, pharmacological
inhibitors of HSL have been proposed for the treatment of
cancer-associated cachexia [4] and a number of com-
pounds have been synthesized and characterized [6, 7].
However, the impact of HSL suppression on cancer devel-
opment has not been examined.
Pancreatic ductal adenocarcinoma (PDAC) is an ex-
tremely aggressive disease with an overall 5-year survival
rate of about 8% [8]. Currently, it is the fourth leading
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cause of cancer deaths in both men and women [8]. PDAC
mortality is projected to increase, and before the year 2030
it is expected to become the second leading cause of
cancer-related deaths [9]. Cachexia is a prominent condi-
tion in PDAC that severely restricts therapeutic options.
Therefore, the development of pharmacological agents that
can attenuate or reverse cachexia in the context of PDAC is
of clinical importance. Administration of inhibitors of HSL
have been proposed in the management of cachexia [4] but
the precise effect of chronic HSL suppression on the pro-
gression of PDAC has never been examined.
HSL null mice appear phenotypically normal (with the
exception of infertility in males due to severe oligo- or
azoospermia) and are resistant to diet-induced and genetic
obesity [10]. In order to assess the role of HSL in PDAC de-
velopment, we generated conditional KrasG12D mice with
HSL deficiency. We found that KC mice with HSL defi-
ciency, compared to KC mice with functional HSL, had
similar weight gain and enhanced adipose tissue (AT) and
pancreatic inflammation. Surprisingly, KC mice with HSL
deficiency exhibited an increased incidence of PDAC. Our
results strongly indicate that HSL deficiency is sufficient to
accelerate PDAC development in KC mice and therefore
imply that chronic suppression of HSL has an unrecognized
tumor promoting effect in the KC model.
Methods
Conditional KrasG12D mouse model with HSL deficiency
The conditional KrasG12D (KC) mouse model from
Hingorani and colleagues was used for this study [11]. In
the KC (LSL-KrasG12D;p48-Cre) strain, expression of onco-
genic KrasG12D is activated by Cre-mediated excision of
LoxP-Stop-LoxP (LSL) in pancreatic lineages during early
embryonic development when the Ptf1a/p48 promoter is ac-
tive. HSL deficient mice were kindly provided by Fredric
Kraemer at Stanford University [10]. Hsl+/− mice were
crossed into p48-Cre+/− and LSL-KrasG12D+/− mice to ob-
tain p48-Cre+/−;Hsl+/− and LSL-KrasG12D+/−;Hsl+/− double
mutants. The double mutant mice were crossed to generate
the desired triple mutant genotypes: LSL-KrasG12D+/
−;p48-Cre+/−;Hsl+/+ (KC;Hsl+/+), LSL-KrasG12D+/−;p48-Cre+/
−;Hsl+/− (KC;Hsl+/−), and LSL-KrasG12D+/−;p48-Cre+/−;Hsl−/
− (KC;Hsl−/−) (Figs. 1a, b). Mice were fed regular chow be-
ginning at one month of age until 20 weeks of age. We
A
C D
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Fig. 1 a Breeding scheme to generate KC;Hsl+/+, KC;Hsl+/−, and KC;Hsl−/− mice. b Exon structure of wildtype and HSL deficient mice. Replacing
portions of exon 5 and the entire exon 6 with a neo cassette renders mice functionally HSL deficient [10]. Representative genotyping result
showing a single 320 bp band in Hsl−/− mice, a single 269 bp band in Hsl+/+ mice, and a double band (320 bp and 269 bp) in Hsl+/− mice.
c Weight curves of female and male KC;Hsl+/+ (n = 9 males+ 14 females), KC;Hsl+/− (n = 20 males+ 23 females), and KC;Hsl−/− (n = 10 males+ 10
females) mice fed standard rodent chow for 20 weeks. d Plasma levels of cholesterol, triglycerides, glucose, insulin, and leptin in KC;Hsl+/+ and
KC;Hsl−/− mice at 6 months (at sacrifice). N = 6
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analyzed 23 KC;Hsl+/+, 43 KC;Hsl+/−, and 20 KC;Hsl−/− mice.
Animal studies were approved by the Chancellor’s Animal
Research Committee of the University of California, Los
Angeles (UCLA) in accordance with the National Institutes
of Health Guide for the Care and Use of Laboratory Ani-
mals. All mice were sacrificed under general anesthesia with
isoflurane. None of the animals died without euthanasia.
Genotyping analysis
The LSL-KrasG12D, p48-Cre, and Hsl alleles were geno-
typed by polymerase chain reaction (PCR) analysis as de-
scribed elsewhere [10, 12].
Blood metabolic panel
Blood samples were collected from mice by intracardiac
puncture at euthanasia. Blood chemistry (plasma choles-
terol, glucose, and triglycerides levels) was obtained by the
DLAM Pathology & Laboratory Medicine Services at
UCLA. Levels of plasma insulin and leptin were determined
using the MILLIPLEX MAP Mouse Adipokine Magnetic
Bead Panel - Endocrine Multiplex Assay (EMD Millipore,
Billerica, MA) based on the manufacturer’s instructions.
Adipose tissue inflammation
Formalin-fixed AT was paraffin-embedded and sec-
tioned. Hematoxylin and eosin (H.E.)-stained sections
were analyzed on a Nikon Eclipse 90i microscope
(Nikon, Melville, NY) equipped with NIS AR4.2 software
(Nikon). Crown-like structures (CLS) representing in-
flammatory foci [13, 14] were quantified and described
as number per high-power field (hpf ). A CLS was de-
fined as one adipocyte surrounded by inflammatory cells
at least partially. For each tissue sample, ten images were
taken, and the number of CLS per 10 randomly selected
adipocytes were quantified.
Cytokine array
Mesenteric fat homogenates from KC;Hsl+/+ and KC;Hsl−/−
mice were profiled using the Mouse Cytokine Antibody
Array, C1000 (RayBiotech, Norcross, GA) following the
manufacturer’s instructions. The membrane-based prote-
omic array detects relative levels of 96 different cytokines
and chemokines. The complete list of cytokines and
chemokines analyzed can be found here: https://www.ray-
biotech.com/c-series-mouse-cytokine-array-c1000-2/. Fol-
lowing exposure to horseradish peroxidase (HRP) the
membranes were imaged using the ChemiDoc™ Touch
Imaging System (Bio-Rad Laboratories, Hercules, CA), and
the intensity of signals normalized to the internal positive
controls was quantified with Multi Gauge V3.0 software
(Fujifilm Life Sciences, Tokyo, Japan).
Pancreas histology
Formalin-fixed, paraffin-embedded pancreatic tissue sec-
tions were stained with hematoxylin and eosin and his-
tologically analyzed in a blinded fashion. Murine
pancreatic intraepithelial neoplasia (PanINs) and inva-
sive PDAC were classified according to histopathologic
criteria as previously described [15–17].
Quantification of lipid content
Tissue content of triglycerides (TG), phospholipids (PL),
and free fatty acids (FFA) and the fatty acid (FA) profile
in each lipid fraction was analyzed by the Vanderbilt
Mouse Metabolic Phenotyping Center. Briefly, phospho-
lipids, diglycerides, triglycerides, and cholesteryl esters
in the extracted lipids were separated by thin layer chro-
matography, scraped from the plates and methylated.
The methylated FA were then extracted and analyzed on
an Agilent 7890A gas chromatograph. FA methyl esters
were identified by comparing the retention times to
those of known standards. Inclusion of lipid standards
with odd chain FAs allowed quantitation of lipids in the
sample. Dipentadecanoyl phosphatidylcholine (C15:0),
diheptadecanoin (C17:0), trieicosenoin (C20:1), and cho-
lesteryl eicosenoate (C20:1) were the standards used.
Immunohistochemistry
Paraffin was removed with xylene and graded alcohol.
Heat-induced antigen retrieval was performed with cit-
rate buffer, and endogenous peroxidase activity was
blocked with 3% hydrogen peroxide. Slides were then in-
cubated overnight with polyclonal rabbit primary anti-
bodies against HSL (Novus Biologicals, Littleton, CO) or
monoclonal rabbit primary antibodies against Ki67 (Cell
Signaling Technologies, Danvers, MA). Control images
were prepared using isotype matched rabbit IgG (Cell
Signaling Technologies). Images were analyzed on a
Nikon Eclipse 90i microscope equipped with NIS AR4.2
software (Nikon). Ki67 staining was quantified by count-
ing Ki67 positive cells (stromal and epithelial) in 10
high-power fields per tissue section.
Immunofluorescence
Paraffin was removed with xylene and graded alcohol. Anti-
gen retrieval was performed by using Antigen Unmasking
Solution (Vector Laboratories, Burlingame, CA) plus ethyl-
enediaminetetraacetic acid (EDTA). Endogenous peroxidase
activity was blocked with 1% hydrogen peroxide. Slides were
then incubated overnight with monoclonal rabbit anti-F4/80
antibody (clone SP115, Novus Biologicals) and monoclonal
mouse anti-TNF-α (tumor necrosis factor alpha) antibody
(clone SPM543, Novus Biologicals). Anti-rabbit IgG anti-
bodies conjugated with Alexa Fluor 555 (Thermo Fisher
Scientific, Canoga Park, CA) and anti-mouse IgG antibodies
conjugated with Alexa Fluor 488 (Thermo Fisher Scientific)
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were added at room temperature for one hour. Images were
analyzed on a Nikon Eclipse 90i microscope equipped with
NIS AR4.2 software (Nikon). F4/80 and TNF-α positive cells
were counted in 10 hpf per tissue section and analyzed as 0
(no staining), + (1–5 cells/hpf ), ++ (5–10 cells/hpf ),
and +++ (> 10 cells/hpf ).
Western blot analysis
Mouse tissue samples were homogenized in radio-im-
munoprecipitation assay (RIPA) buffer containing mix-
ture of protease and phosphatase inhibitors (Roche
Applied Science, Basel, Switzerland). Tissue homoge-
nates were resolved by SDS-PAGE, electrophoretically
transferred onto nitrocellulose membranes, and then immu-
noblotted for the proteins of interest using the following pri-
mary antibodies: Peroxisome proliferator-activated receptor
gamma (PPAR-γ) and p44/42 MAPK from Cell Signaling
Technologies, and HSL from Novus Biologicals. After incu-
bation with secondary antibodies, the immune-reactive
bands detected with enhanced chemiluminescence reagents
were imaged and analyzed by the ChemiDoc™ Touch
Imaging System (Bio-Rad Laboratories).
PCR analysis of Hsl
Total RNA from tissue or cell lysates were extracted using
RNA purification kits (Biomiga, Inc., San Diego, CA). Re-
verse transcription was performed with the iScript reverse
transcription supermix (Bio-Rad Laboratories). The syn-
thesized cDNA was used as template for the PCR analysis
of Hsl gene expression. The iTaq™ Supermix (Bio-Rad La-
boratories) was used for amplifications. All reactions were
performed on the Bio-Rad iQ™5 system. Primers for
mouse Hsl: forward, 5′- GCAGTGGTGTGTAACTAGG
ATTG-3′, and reverse, 5′- CGCTGAGGCTTTGA
TCTTGC -3′ (spanning exons 1 and 2).
Statistical analysis
Data are presented as mean ± SD. Statistical significance
was determined by one-way (or two-way) ANOVA and
two-tailed Student’s t-tests assuming unequal variances.
For the comparison of PDAC incidence, a two-sided
Fisher’s exact test was performed. Significance (p-value
less than 0.05) was indicated with an asterisk (*).
Results
Weight gain and metabolic parameters in KC mice with
HSL deficiency
After weaning female and male KC;Hsl+/+, KC;Hsl+/−,
and KC;Hsl−/− mice were fed regular rodent chow for
20 weeks. Although females gained less weight than
male mice, KC;Hsl+/+, KC;Hsl+/−, and KC;Hsl−/− mice
within each gender group gained weight similarly
throughout the study period (Fig. 1c), which is in ac-
cordance with previous reports [10, 18]. Compared to
KC;Hsl+/+ mice, KC;Hsl−/− mice showed reduced plasma
TG levels, while cholesterol levels were unchanged (Fig.
1d). Our studies demonstrated reduced plasma insulin
levels in KC;Hsl−/− mice with normal glucose concentra-
tions (Fig. 1d), suggesting enhanced insulin sensitivity.
Furthermore, KC;Hsl−/− mice had reduced plasma levels
of leptin (Fig. 1d), a hormone secreted primarily by adi-
pocytes of white adipose tissue (WAT).
KC mice with HSL deficiency display enhanced AT
inflammation
We have previously reported an enhanced depot-specific
AT inflammation during diet-induced obesity (DIO) in
KC mice [14]. In the present study, histological examin-
ation revealed increased WAT (mesenteric depot) inflam-
mation in KC;Hsl−/− mice as assessed by quantification of
CLS (Fig. 2a). The increase in CLS was accompanied by
an enhanced presence of TNF-α expressing F4/80-positive
cells (macrophages) in the mesenteric WAT of KC;Hsl−/−
mice as assessed by immunofluorescence (Fig. 2b). De-
tailed tissue lipid analysis revealed decreased TG content
in mesenteric WAT of KC;Hsl−/− mice as well as reduced
expression of pro-adipogenic PPAR-γ (Fig. 2c), confirming
the impairment of adipogenesis in HSL null mice [18].
The anti-adipogenic phenotype associated with HSL
deficiency is consistent with the role of HSL in providing
intrinsic ligands for PPARγ through release of FAs [19].
The PL content in mesenteric WAT was unchanged in
KC;Hsl−/− mice, reflecting the lack of phospholipase activ-
ity of HSL. Despite the physiological role of HSL in FA re-
lease, the levels of FFA in the mesenteric WAT of
KC;Hsl−/− mice were unaltered (Fig. 2c). Due to limited
amount of tissue available for each analysis, we did not
measure the intracellular levels of diacylglycerols, which
are known to accumulate in tissues of Hsl−/− mice due to
the importance and preference of HSL to hydrolyze diac-
ylglycerols [20]. Using a Mouse Cytokine Antibody Array,
multiple changes in cytokines and chemokines were de-
tected in the mesenteric WAT of KC;Hsl−/− mice (Fig. 2d).
Significant elevations of adhesion molecules (e.g. ICAM-1,
L-selectin) and chemokines (e.g. MIP-1 gamma, CCL5,
CCL22) were found (Fig. 2d) that may reflect AT inflam-
mation with recruitment and infiltration of immune cells
into the mesenteric WAT.
KC mice with HSL deficiency have an increased incidence
of PDAC
Consistent with previous reports [21], HSL was
expressed in pancreatic islets of wild type (WT) mice
(Fig. 3a). Interestingly, immunohistochemistry showed
strong HSL expression in PanIN lesions of KC;Hsl+/+
and KC;Hsl−/− mice (Fig. 3a), which has never been de-
scribed before. Expression of HSL in PanIN cells was
confirmed by PCR analysis of primary PanIN cells
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isolated from KC mice (with functional HSL) and cul-
tured in vitro (Fig. 3b). Despite the functional HSL defi-
ciency in KC;Hsl−/− mice (by virtue of replacing portions
of exon 5 and the entire exon 6 with a neo cassette), the
antibodies used in the present study seem to be able to
detect the non-functional HSL protein in KC;hsl−/− mice.
It is unclear whether the apparent lower expression of
HSL in KC;Hsl−/− WAT and pancreatic lysates (Fig. 2c
and 3b) is caused by an actual decreased expression or
by a lower affinity of the antibody to the non-functional
HSL protein. Detailed pancreatic tissue lipid analysis
demonstrated markedly reduced TG and FFA content in
KC;Hsl−/− mice (Fig. 3c). Again, the PL content was un-
altered in the pancreas of KC;Hsl−/− mice (Fig. 3c).
The most salient feature of this study is that KC;Hsl−/−
mice displayed a significantly increased PDAC incidence
at 20 weeks (Fig. 4a). While none of the KC;Hsl+/+ mice
developed invasive PDAC at six months of age, 25% (5/
20) of KC;Hsl−/− mice had cancer (p = 0.016). The in-
creased PDAC incidence in KC;Hsl−/− mice was thereby
associated with an elevated proliferation of PanIN and
stromal cells (Fig. 4b) as assessed by Ki67 immunostain-
ing. Furthermore, KC;Hsl−/− mice displayed enhanced
pancreatic inflammation as evident histologically and by
an increase in TNF-α expressing F4/80-positive macro-
phages assessed by immunofluorescence (Fig. 4c).
Patients with PDAC and low expression of LIPE have
unfavorable prognosis
To assess the significance of HSL expression in human
PDAC, we determined the importance of the expression
of the gene encoding HSL as a prognostic marker of sur-
vival in patients with PDAC. We used a recently published
interactive open-access database (www.proteinatlas.org/
pathology) to perform correlation analyses based on
mRNA expression levels of LIPE (the gene encoding HSL)
A
C
D
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Fig. 2 a Representative histology (H.E. staining) of the mesenteric WAT of KC;Hsl+/+ and KC;Hsl−/− mice. Scale bar represents 100 μm. Quantification of
crown-like structures (CLS) in KC;Hsl+/+ and KC;Hsl−/− mice (right). *: p < 0.01. b Immunofluorescence staining of mesenteric WAT of KC;Hsl+/+ and
KC;Hsl−/− mice (two representative mice in each group). Red and green staining denote F4/80 (macrophage marker) and TNF-α (as a marker of tissue
inflammation), respectively. Scale bar represents 100 μm. Semi-quantitative analysis of TNF-α expressing macrophages (orange staining) in KC;Hsl+/+
and KC;Hsl−/− mice (table below). c Quantification of PL, TG, and FFA content in mesenteric WAT of KC;Hsl+/+ and KC;Hsl−/− mice (n = 5). Western blot
analysis of HSL and PPAR-γ (total ERK as loading control) in KC;Hsl+/+ and KC;Hsl−/− mice (lower left). d Changes (≥ 50% increase or decrease compared
to KC;Hsl+/+) in several cytokines and chemokines in the mesenteric WAT of KC;Hsl−/− mice as detected by a Mouse Cytokine Antibody Array (n = 3
biological replicates). Representative array blots (Cytokine Array 3 and 4) in KC;Hsl+/+ and KC;Hsl−/− mice (right)
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in PDAC tissue and the clinical outcome (survival) of the
patients. The data in the Pathology Atlas is based on the
analysis of transcriptomics and survival in 176 PDAC pa-
tients. As illustrated in the Kaplan-Meier plot in Fig. 5,
none of the patients of the population with lower levels of
LIPE mRNA expression (n = 69) survived for 5 years while
42% of the population (n = 107) with the higher levels of
LIPE mRNA survived for 5 years or more.
Discussion
A striking feature of the results presented here is that
KC mice lacking HSL (KC;Hsl−/−) mice displayed a sig-
nificant increase in PDAC incidence. To our knowledge,
it is the first time that HSL deficiency has been linked to
an increased cancer risk. In humans, carriers of a frame-
shift deletion of exon 9 in the LIPE gene, encoding for
HSL, were characterized by metabolic dysfunction, in-
cluding dyslipidemia, hepatic steatosis, systemic insulin
resistance, and diabetes [22]. In the adipose tissue from
carriers with the mutation, impaired lipolysis and in-
flammation were observed [22]. In our study, the exact
mechanism(s) involved in promoting PDAC remains in-
completely understood. HSL deficiency in KC mice was
accompanied by enhanced inflammation in the AT and
pancreas. While CLS is a well-characterized feature of
adipose tissue inflammation (macrophages surrounding
necrotic adipocytes), additional analysis is warranted to
further identify inflammatory cell subpopulations. It has
been postulated that an increased heterogeneity of adi-
pocytes with necrotic cell death of hypertrophic adipo-
cytes and subsequent infiltration of macrophages may
play an important role in inducing WAT inflammation
in the context of HSL deficiency [10, 23]. Lipid analysis
of the mesenteric WAT in KC;Hsl−/− mice has revealed a
decreased TG content, in agreement with previous re-
ports [24]. The mechanistic link between HSL deficiency
and TG reduction in WAT was suggested to be a com-
pensatory downregulation of FA esterification enzymes,
leading to reduced cellular TG synthesis [25]. This ob-
servation is consistent with the reported impairment of
white adipocyte differentiation and decreased WAT
mass in HSL null mice [18]. The anti-adipogenic pheno-
type may also be mediated by a decrease in PPAR-γ ex-
pression and activity through the reduced intracellular
release of FAs, acting as endogenous PPAR-γ ligands, in
HSL null mice [19]. This is corroborated by our finding
of reduced PPAR-γ expression in the mesenteric WAT
of KC;Hsl−/− mice. FFA levels in the mesenteric WAT
were not significantly altered in KC;Hsl−/− mice, which
can be explained by the presence of additional lipases
in the WAT, i.e. adipose triglyceride lipase, which
preferentially catalyzes the conversion of triacylglyc-
erol to diacylglycerol and thereby maintaining a FFA
pool in WAT [24].
In addition to AT inflammation, KC;Hsl−/− mice also
had enhanced pancreatic inflammation as demonstrated
A
B C
Fig. 3 a Representative HSL immunohistochemistry of the pancreas in wildtype, KC;Hsl+/+, and KC;Hsl−/− mice showing HSL positivity in pancreatic
islets and PanIN cells. Scale bar represents 100 μm. b HSL western blot of total pancreatic lysates in KC;Hsl+/+ and KC;Hsl−/− mice (GAPDH as loading
control). PCR analysis of Hsl transcripts in differentiated 3 T3-L1 (adipocytes), murine PanIN (mPanIN) and murine PDAC cells (both isolated from KC
mice), murine pancreas and liver (lower). c Quantification of PL, TG, and FFA content in the pancreas of KC;Hsl+/+ and KC;Hsl−/− mice (n = 5). *: p < 0.01
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histologically and by an increased number of TNF-α
producing macrophages in the pancreas. It is currently
unclear what mechanisms elicited the pancreatic inflam-
mation seen in KC;Hsl−/− mice. It is possible that HSL
deficiency causes enhanced inflammation primarily in
the visceral WAT adjacent to the pancreas with an in-
creased production and secretion of pro-inflammatory
cytokines, which could elicit a subsequent inflammatory
reaction in the pancreas of KC mice. This is supported
by our finding that HSL deficiency failed to cause pan-
creatic inflammation in WT mice. It is conceivable that
the robust visceral WAT inflammation in KC;Hsl−/−
mice reinforces and amplifies the oncogenic and inflam-
matory signaling in KrasG12D harboring pancreatic
cells, thereby leading to substantial pancreatic inflamma-
tion and accelerated PDAC development.
However, we cannot rule out an important role of pan-
creatic HSL in mediating pancreatic inflammation and
tumorigenesis. Indeed, we detected strong HSL expres-
sion in pancreatic islets and PanIN lesions and reduced
expression of LIPE (the gene encoding HSL) in pancre-
atic tissue of patients with PDAC is associated with de-
creased overall survival [26]. HSL deficiency in
pancreatic islets may thereby explain the observed re-
duction in insulin of KC;Hsl−/− mice in our study, as
HSL has been described to be important in
glucose-stimulated insulin secretion in pancreatic beta
cells [27]. HSL deficiency in the pancreas was accom-
panied by reduced TG and FFA levels, indicating a
prominent role of HSL (and a possible absence of add-
itional neutral lipases) in FFA release from intracellular
TG depots in the pancreas. It is plausible that in the
A
B
C
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Fig. 4 a Representative histology (H.E. staining) of the pancreas of Hsl−/−, KC;Hsl+/+, KC;Hsl+/−, and KC;Hsl−/− mice. Scale bar represents 100 μm. No
pancreatic neoplastic lesions were detected in Hsl−/− mice. Analysis of PDAC incidence at 20 weeks (sacrifice) in KC;Hsl+/+, KC;Hsl+/−, and KC;Hsl−/−
mice (table right). b Ki67 immunohistochemistry of the pancreas of KC;Hsl+/+ and KC;Hsl−/− mice. Scale bar represents 100 μm. Quantification of
Ki67 immunoreactivity in epithelial (ductal, indicated by solid arrows) and stromal cells (indicated by hollow arrows). N = 6, *: p< 0.01. c Immunofluorescence
staining of the pancreas of KC;Hsl+/+ and KC;Hsl−/− mice (two representative mice in each group). Scale bar represents 100 μm. Red and green staining
denote F4/80 (macrophage marker) and TNF-α (as a marker of tissue inflammation), respectively. Semi-quantitative analysis of TNF-α expressing macrophages
(orange staining) in KC;Hsl+/+ and KC;Hsl−/− mice (table below)
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presence of oncogenic KRAS these lipid changes locally
in the pancreas in KC;Hsl−/− mice are driving promo-
tional factors of pancreatic inflammation and PDAC de-
velopment. These possibilities are not mutually exclusive
and the lack of HSL in both visceral WAT and in the
pancreas of KC could cooperate in accelerating PDAC
development.
Conclusion
Our data demonstrated that HSL deficiency in KC mice
leads to inflammation of mesenteric WAT and the pancreas
and importantly accelerated PDAC formation. Collectively,
our results revealed an unexpected tumor-suppressive role
of HSL and emphasize the need of caution in targeting HSL
for tumor cachexia or dyslipidemia, as chronic suppression
of this enzyme may lead to increased incidence of PDAC.
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